Wilton P, Sietnieks A, Gunnarsson R, Berger L, Grahnén A
Department of Clinical Research, Kabi Pharmacia Peptide Hormones, Stockholm, Sweden.
Acta Paediatr Scand Suppl. 1991;377:111-4. doi: 10.1111/apa.1991.80.s377.111.
The pharmacokinetic profile of recombinant human insulin-like growth factor I (IGF-I) was studied in healthy volunteers. Following a single subcutaneous injection of 40 micrograms/kg or 80 micrograms/kg, mean serum IGF-I concentrations increased by 150 ng/ml and 245 ng/ml, respectively. During repeated daily injections of 40 micrograms/kg, a steady-state IGF-I level of 150 ng/ml above baseline was reached. Of the pharmacokinetic indices measured, only Tmax varied between single and multiple dose regimens (6.9 hours versus 3.5 hours). No hypoglycaemic symptoms were observed, and after injection of IGF-I no depression of endogenous IGF-I production was observed. Fasting insulin levels were unaltered, but postprandial insulin was lowered by IGF-I with respect to placebo.
在健康志愿者中研究了重组人胰岛素样生长因子I（IGF-I）的药代动力学特征。单次皮下注射40微克/千克或80微克/千克后，血清IGF-I平均浓度分别升高了150纳克/毫升和245纳克/毫升。在每日重复注射40微克/千克的过程中，IGF-I水平达到了比基线高150纳克/毫升的稳态。在所测量的药代动力学指标中，只有达峰时间（Tmax）在单剂量和多剂量方案之间有所不同（分别为6.9小时和3.5小时）。未观察到低血糖症状，注射IGF-I后也未观察到内源性IGF-I产生受到抑制。空腹胰岛素水平未改变，但与安慰剂相比，IGF-I使餐后胰岛素水平降低。
